Merrill Lynch Resumes Coverage on Gilead Sciences (GILD)
More News related to GILD
- Gilead Sciences to Present at Two Upcoming Investor Conferences
- Gilead Sciences Announces Notification of ANDA Filing for Truvada
- David Moenning's Daily State of the Markets: 11/12
- Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
- Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding
More News related to New Coverage
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Merrill Lynch resumes coverage on Gilead Sciences (Nasdaq: GILD) with a Neutral.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
New CoverageStocks Mentioned
+1.63Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
